Get the Stockscreener App
0.5301
5.34%
-0.0299
After Hours:
.49
-0.0401
-7.56%
Immunoprecise Antibodies Ltd stock is traded at $0.5301, with a volume of 639.50K.
It is down -5.34% in the last 24 hours and up +23.31% over the past month.
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.
See More
Previous Close:
$0.56
Open:
$0.535
24h Volume:
639.50K
Relative Volume:
1.11
Market Cap:
$16.47M
Revenue:
$16.77M
Net Income/Loss:
$-11.87M
P/E Ratio:
-1.1179
EPS:
-0.4742
Net Cash Flow:
$-5.90M
1W Performance:
+0.30%
1M Performance:
+23.31%
6M Performance:
-41.75%
1Y Performance:
-62.14%
1-Day Range:
$0.49
$0.5499
1-Week Range:
$0.4301
$0.59
52-Week Range:
$0.3248
$2.60
Immunoprecise Antibodies Ltd Stock (IPA) Company Profile
Name
Immunoprecise Antibodies Ltd
Sector
Industry
Phone
-
Address
-
Compare IPA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPA
Immunoprecise Antibodies Ltd
|
0.5301 | 16.47M | 16.77M | -11.87M | -5.90M | -0.4742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunoprecise Antibodies Ltd Stock (IPA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Oct-25-21 | Initiated | The Benchmark Company | Buy |
Immunoprecise Antibodies Ltd Stock (IPA) Latest News
ImmunoPrecise Antibodies Ltd. (IPA) Launches AI-Powered Drug Discovery Pipeline, Revolutionizing Therapeutic Development with LENSai™ Platform - Yahoo Finance
10 Trending AI Stocks on Latest News and Ratings - Insider Monkey
ImmunoPrecise launches AI-driven drug discovery pipeline - Investing.com India
ImmunoPrecise Antibodies Launches AI-Powered Drug Discovery Platform - TipRanks
ImmunoPrecise Launches Groundbreaking AI Platform LENSai for Revolutionary Drug Discovery - StockTitan
Even With A 30% Surge, Cautious Investors Are Not Rewarding ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Performance Completely - Simply Wall St
ImmunoPrecise Antibodies (NASDAQ:IPA) Stock Price Up 15.5% – What’s Next? - Defense World
ImmunoPrecise Antibodies Announces CFO Resignation - TipRanks
ImmunoPrecise Antibodies finance chief to step down - MSN
ImmunoPrecise Antibodies announces resignation of CFO - Yahoo Finance
ImmunoPrecise Antibodies Ltd. Announces the Resignation of Kristin Taylor as Chief Financial Officer, Effective January 16, 2025 - Marketscreener.com
ImmunoPrecise Antibodies CFO Resignation and Succession - TipRanks
ImmunoPrecise Antibodies CFO Kristin Taylor Announces Resignation, Will Transition Through January 2025 - StockTitan
IPA Announces Resignation of Chief Financial Officer - Business Wire
ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases - The Globe and Mail
ImmunoPrecise CEO Leads Major $306K Insider Stock Purchase, Signals Confidence in AI-Driven Strategy - StockTitan
ImmunoPrecise Antibodies to Present at Microcap Conference 2025: AI-Driven Biotech Showcase - StockTitan
ImmunoPrecise Antibodies to Showcase at Microcap Conference - TipRanks
IPA to Present at The Microcap Conference 2025 - Business Wire
HC Wainwright Has Optimistic Outlook of IPA Q3 Earnings - Defense World
Research Analysts Set Expectations for IPA FY2028 Earnings - Defense World
Immunoprecise shares target cut, retains buy rating on potential By Investing.com - Investing.com Nigeria
Immunoprecise shares target cut, retains buy rating on potential - Investing.com
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q2 2025 Earnings Call Transcript - Insider Monkey
ImmunoPrecise Antibodies Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
ImmunoPrecise Antibodies Ltd (IPA) Q2 2025 Earnings Call Highlig - GuruFocus.com
ImmunoPrecise Antibodies Ltd (IPA) Q2 2025 Earnings Call Highlights: Strategic Moves and Growth ... - Yahoo Finance
ImmunoPrecise Antibodies Ltd (IPA) Q2 2025 Earnings Call Highlights: Strategic Moves and Growth ... By GuruFocus - Investing.com Canada
ImmunoPrecise Antibodies Reports Mixed Financial Results - TipRanks
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q2 Loss, Misses Revenue Estimates - MSN
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com
Immunoprecise Antibodies Ltd reports results for the quarter ended October 31Earnings Summary - XM
ImmunoPrecise Antibodies Reports Q2 Results and Strategic Advances in AI-Driven Drug Discovery - TipRanks
ImmunoPrecise Antibodies Expands with Strategic Growth in Biologics and CRO Services - TipRanks
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 - Business Wire
ImmunoPrecise Antibodies Unveils Strategic BioNTech & Mayo Clinic Partnerships Amid Q2 Earnings Report - StockTitan
IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference - Business Wire
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024 - The Globe and Mail
ImmunoPrecise Antibodies to Announce Q1 Financial Results - TipRanks
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
Immunoprecise Antibodies Ltd. Announces Resignation of Barry A. Springer from Board - Marketscreener.com
ImmunoPrecise's Breakthrough Cancer Treatment Shows Promise in $20.7B ADC Market | IPA Stock News - StockTitan
$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies - Business Wire
ImmunoPrecise Antibodies (NASDAQ:IPA) Stock Price Down 2% – Here’s What Happened - Defense World
ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation - BioSpace
ImmunoPrecise Pummeled Despite Advancing Anti-Aging Research with Mayo - Baystreet.ca
ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology - Business Wire
ImmunoPrecise Antibodies Announces Annual Meeting Plans - TipRanks
ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024 - BioSpace
ImmunoPrecise touts potential of rabbit monoclonal antibodies in oncology - Pharmaceutical Technology
ImmunoPrecise Antibodies to Join AI Drug Summit - TipRanks
Immunoprecise Antibodies Ltd Stock (IPA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):